Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 18/20 | 0.78 |
| ▸ | ADRA2B | P18089 | 18/20 | 0.78 |
| ▸ | ADRA2C | P18825 | 18/20 | 0.78 |
| ▸ | PTGIR | P43119 | 1/20 | 0.73 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11180468 | 0.96 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CPTGIRADRA1D | |
| SCHEMBL11283477 | 0.89 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CPTGIR | |
| Benzaldehyde SCHEMBL5084142 | 0.87 | ADRA2A (0.60) | ADRA2AADRA2BADRA2CPTGIRADRA1D | |
| Benzophenone SCHEMBL5084127 | 0.87 | ADRA2A (0.80) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL11162946 | 0.85 | NISCH (0.59) | ADRA2AADRA2BADRA2CPTGIRADRA1D | |
| SCHEMBL11163847 | 0.85 | ADRA2A (0.88) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL5802197 | 0.85 | PTGIR (1.00) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL5803227 | 0.85 | ADRA2A (0.88) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL13017193 | 0.85 | ADRA2A (0.88) | ADRA2AADRA2BADRA2CPTGIRADRA1D | |
| Hydrochloric Acid SCHEMBL11166308 | 0.84 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2276472-B1 | COMPOSITIONS COMPRISING WEAKLY BASIC DRUGS AND CONTROLLED-RELEASE DOSAGE FORMS | ADARE PHARMACEUTICALS INC (US) | 2018-11-21 | — | — | EP | claimed |
| CN-104874021-A | Method for preparing forging bone for surgical implantation | BEIJING AOSITESAI MEDICAL TECHNOLOGY CO LTD | 2015-09-02 | — | — | CN | claimed |
| CN-102006862-A | Compositions and controlled release dosage forms comprising weakly basic drugs | EURAND INC | 2011-04-06 | — | — | CN | claimed |
| EP-2276472-A1 | COMPOSITIONS COMPRISING WEAKLY BASIC DRUGS AND CONTROLLED-RELEASE DOSAGE FORMS | Eurand, Inc. (US) | 2011-01-26 | — | — | EP | claimed |
| WO-2009129282-A1 | COMPOSITIONS COMPRISING WEAKLY BASIC DRUGS AND CONTROLLED-RELEASE DOSAGE FORMS | EURAND INC (US) | 2009-10-22 | — | — | WO | claimed |
| US-20090258066-A1 | COMPOSITIONS COMPRISING WEAKLY BASIC DRUGS AND CONTROLLED-RELEASE DOSAGE FORMS | ADARE PHARMACEUTICALS USA, INC. | 2009-10-15 | — | — | US | claimed |
| EP-0821585-B1 | USE OF ALPHA 1L-AGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-01-10 | — | — | EP | claimed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | claimed |
| US-20020040150-A1 | SKIN TREATMENT COMPOSITONS CONTAINING A CATIONIC POLYMER AND A MICROPARTICLE OR NANOPARTICLE VECTOR | ESSER FRANZ (DE) | 2002-04-04 | — | — | US | claimed |
| CN-1180311-A | Use of 'alpha' 1L agonists in treatment of incontinence | BOEHRINGER INGELHEIM KG (DE) | 1998-04-29 | — | — | CN | claimed |
| EP-0029505-B1 | SUBSTITUTED PHENYLAMINO-2-IMIDAZOLINE-2 DERIVATIVES, THEIR ACID ADDITION SALTS, MEDICAMENTS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | C.H. BOEHRINGER SOHN (DE) | 1984-09-12 | — | — | EP | claimed |
| EP-0030620-B1 | SUBSTITUTED 2-PHENYLAMINO-2-IMIDAZOLINES, ACID ADDITION SALTS THEREOF, MEDICAMENTS CONTAINING THEM AND PROCESS FOR PREPARING THEM | C.H. BOEHRINGER SOHN (DE) | 1984-06-13 | — | — | EP | claimed |
| EP-0030616-B1 | SUBSTITUTED 2-PHENYLAMINO-2-IMIDAZOLINES, THEIR ACID ADDITION SALTS, MEDICAMENTS CONTAINING THEM AND PROCESSES FOR PREPARING SAME | C.H. BOEHRINGER SOHN (DE) | 1984-01-11 | — | — | EP | claimed |
| US-4262006-A | BRADYCARDIZING ACTIVITY, HYPOTENSIVE, DIURETIC | ISTITUTO LUSOFARMACO D'ITALIA S.P.A. (IT) | 1981-04-14 | — | — | US | claimed |
| CN-112472715-B | Sodium bicarbonate enteric capsule and preparation method thereof | 华熙生物科技股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-112472715-A | Sodium bicarbonate enteric-coated capsule and preparation method thereof | 华熙生物科技股份有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-10583195-B2 | Conjugate with target-finding ligand and use thereof | ETHRIS GMBH (DE) | 2020-03-10 | — | — | US | disclosed |
| US-3998956-A | Pharmaceutical compositions containing a 1-(thienyl-methyl)-2-anilino-2-imidazoline and method of use | BOEHRINGER INGELHEIM GMBH (DT) | 1976-12-21 | — | — | US | disclosed |
| US-3950523-A | ANTIDEPRESSANTS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-04-13 | — | — | US | disclosed |
| US-3717633-A | 2-ANILINO-1,3-DIAZACYCLOPENTENE-(2) DERIVATIVE | BOEHRINGER SOHN INGELHEIM | 1973-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | PDE3A, PDE3B, PDE2A | ADRA2A 16/4885ADRA2B 14/4885ADRA2C 12/4885 |
| US-20020040150-A1 | SKIN TREATMENT COMPOSITONS CONTAINING A CATIONIC POLYMER AND A MICROPARTICLE OR NANOPARTICLE VECTOR | COL1A1, TPSAB1, TACR1 | ADRA2A 55/4885ADRA2B 86/4885ADRA2C 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.